Skip to main content
logo
Innate Pharma S.A. (EPA:IPH)
France flag France · Delayed Price · Currency is EUR
1.528
-0.002 (-0.13%)
Aug 3, 2026, 2:51 PM CET

Innate Pharma Financials Overview

Millions EUR. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
9.019.0120.1261.6457.6724.7
Revenue Growth
-28.73%-55.25%-67.36%6.88%133.47%-64.59%
Gross Profit
-34.62-34.62-31.865.626.01-22.3
Operating Income
-54.01-54.01-51.58-12.67-16.43-47.83
Net Income
-49.18-49.18-49.47-7.57-58.1-52.81
Earnings Per Share
-0.55-0.55-0.61-0.09-0.73-0.66
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
34.3134.3180.7792.46101.49119.84
Total Debt
22.5722.573139.8942.2544.25
Net Cash (Debt)
11.7411.7449.7852.5659.2375.59
Net Cash Growth
-64.43%-76.42%-5.30%-11.26%-21.63%-42.98%
Net Cash Per Share
0.130.130.610.650.740.95

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-52.76-52.76-6.9-32.56-19.16-58.46
Capital Expenditures
-0.14-0.14-0.39-0.35-0.54-0.93
Free Cash Flow
-52.9-52.9-7.29-32.91-19.69-59.39
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
---158.34%9.12%10.42%-90.28%
Operating Margin
-599.77%-599.77%-256.32%-20.55%-28.48%-193.60%
Pretax Margin
-546.11%-546.11%-245.87%-12.28%-100.52%-184.10%
Profit Margin
-546.11%-546.11%-245.87%-12.28%-100.74%-213.78%
FCF Margin
-587.40%-587.40%-36.22%-53.39%-34.14%-240.40%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
1.612.994.3310.0410.0458.98
PS Ratio
15.9616.407.953.434.5814.24